Please assess the completion status of the following clinical trial:

Trial Title: Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Patients undergoing elective shoulder surgery by one of two surgeons highly experienced in the procedure.~2. Patients are either: Opioid naïve; or Have not taken opiates for one month prior to surgery (tramadol is permissible).~3. Patients have an American Society of Anesthesiology physical status I-III.~Exclusion criteria:~1. Females who are pregnant.~2. Patients who are taking chronic daily opiates for one month prior to surgery except tramadol.~3. Diabetic patients.~4. Patients with creatinine above 1.1mg/dL for females and above 1.3mg/dL for males.~5. Patients with contralateral pneumothorax or diaphragmatic paralysis.~6. Patients with coagulopathy.~7. Patients with clinically significant previous nerve injury in surgical extremity.~8. Patients with an allergy to NSAIDs.~9. Patients who are refusing a block.~10. Patients with a contraindication to ropivacaine, dexamethasone, or interscalene block due to other medical condition such as severe chronic obstructive pulmonary disease (COPD).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone block (Type: EXPERIMENTAL): Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
- Dexamethasone IV (Type: ACTIVE_COMPARATOR): Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
- Placebo (Type: PLACEBO_COMPARATOR): Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).